Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Pembrolizumab |
| Indication/Tumor Type | cervical cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | cervical cancer | sensitive | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase II trial (KEYNOTE-158) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in an objective response rate of 14.6% (12/82) in patients with CD274 (PD-L1)-positive (CPS >=1) advanced cervical cancer, including 3 with a complete response and 9 with a partial response (PMID: 30943124; NCT02628067). | 30943124 detail... detail... |
| CD274 positive | cervical cancer | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as second-line or subsequent therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... | |
| Full reference... | ||
| Keytruda (pembrolizumab) FDA Drug Label | Full reference... | |
| (30943124) | Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. | Full reference... |